Trading
Forge Markets Browse Companies
Data
Forge Data IPO Stock Tracker
Solutions
For Investors For Shareholders For Institutions For Companies In Europe
Insights
All Insights Blog Reports Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
About
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Trading
Forge Markets
Browse Companies
Data Data
Forge Data
IPO Stock Tracker
Solutions Solutions
For Investors
For Shareholders
For Institutions
For Companies
In Europe
Insights Insights
All Insights
Blog
Reports
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About About
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Impel NeuroPharma Stock

Impel NeuroPharma Stock

impelnp.comHealthcareFounded: 2008Funding to Date: $122.85MM

Impel NeuroPharma is a biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases.

Learn more about Impel NeuroPharma IPO
Register for Details

For more details on financing and valuation for Impel NeuroPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Impel NeuroPharma.

Register Today

Team

Management Team

Jon Congleton
Chief Executive Officer, President & Board Member
Meghan Swardstrom
Vice President, Clinical Operations
Ellen Lubman
Chief Business Officer
Scott Youmans
Senior Vice President, Engineering
Mike Malafronte
Vice President of Quality Assurance
John Hoekman Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Lynn Gold Ph.D
Senior Vice President, Regulatory
Stephen Shrewsbury
Chief Medical Officer

Board Members

Ali Satvat
Kohlberg Kravis Roberts
H. Stewart Parker
Mahendra Shah Ph.D
Vivo Capital
David Allison Ph.D
5AM Ventures
Diane Wilfong
John Hoekman Ph.D
Robert Mittendorff MD
Norwest Venture Partners
Aaron Royston MD
venBio
James Young Ph.D
5AM Ventures
Jon Congleton
Timothy Nelson

Other companies like Impel NeuroPharma in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Headspace
Sector
Healthcare
Last Round Est. Valuation
$298.33MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
NowRx
Sector
Healthcare
Last Round Est. Valuation
$334.19MM
Theracos
Sector
Healthcare
Last Round Est. Valuation
$327.39MM
OURA
Sector
Healthcare
 
 
Life Biosciences
Sector
Healthcare
Last Round Est. Valuation
$500MM

News

Market Screener 10/17/2019
Impel NeuroPharma : Announces Appointment Of Diane Wilfong To Board Of Directors
FinSMEs 12/07/2018
Impel NeuroPharma Closes $67.5M in Series D Financing | FinSMEs
Impel NeuroPharma, a biotech company focused on developing therapies for the treatment of CNS disorders, completed a $67.5m Series D financing

Trending Companies

Frequently Asked Questions